2188 related articles for article (PubMed ID: 27986682)
1. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.
Jayasinghe S; Chiu C; Menzies R; Lehmann D; Cook H; Giele C; Krause V; McIntyre P
Vaccine; 2015 Nov; 33(48):6666-74. PubMed ID: 26519550
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
[TBL] [Abstract][Full Text] [Related]
4. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
[TBL] [Abstract][Full Text] [Related]
6. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
De Wals P; Lefebvre B; Deceuninck G; Longtin J
Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
[TBL] [Abstract][Full Text] [Related]
7. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause V; Mcintyre P
Clin Infect Dis; 2020 Jun; 70(12):2607-2615. PubMed ID: 31388670
[TBL] [Abstract][Full Text] [Related]
8. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
9. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
[TBL] [Abstract][Full Text] [Related]
10. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
11. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
[TBL] [Abstract][Full Text] [Related]
13. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.
Link-Gelles R; Taylor T; Moore MR;
Vaccine; 2013 May; 31(22):2572-7. PubMed ID: 23583813
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014.
Oligbu G; Collins S; Andrews N; Sheppard CL; Fry NK; Slack MPE; Borrow R; Ladhani SN
Clin Infect Dis; 2017 Oct; 65(7):1191-1198. PubMed ID: 29309553
[TBL] [Abstract][Full Text] [Related]
15. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015.
Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero F; Hernández-Sampelayo T; Otheo E; Méndez C;
PLoS One; 2017; 12(2):e0172222. PubMed ID: 28207888
[TBL] [Abstract][Full Text] [Related]
16. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.
Bertran M; D'Aeth JC; Abdullahi F; Eletu S; Andrews NJ; Ramsay ME; Litt DJ; Ladhani SN
Lancet Infect Dis; 2024 May; 24(5):546-556. PubMed ID: 38310905
[TBL] [Abstract][Full Text] [Related]
17. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom.
Kandasamy R; Voysey M; Collins S; Berbers G; Robinson H; Noel I; Hughes H; Ndimah S; Gould K; Fry N; Sheppard C; Ladhani S; Snape MD; Hinds J; Pollard AJ
J Infect Dis; 2020 Mar; 221(8):1361-1370. PubMed ID: 31004136
[TBL] [Abstract][Full Text] [Related]
18. The rise and fall of pneumococcal serotypes carried in the PCV era.
Devine VT; Cleary DW; Jefferies JM; Anderson R; Morris DE; Tuck AC; Gladstone RA; O'Doherty G; Kuruparan P; Bentley SD; Faust SN; Clarke SC
Vaccine; 2017 Mar; 35(9):1293-1298. PubMed ID: 28161425
[TBL] [Abstract][Full Text] [Related]
19. Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia.
Gidding HF; Sheridan S; Fathima P; Moore HC; Liu B; McIntyre PB; Palmu AA;
Pediatr Infect Dis J; 2019 Aug; 38(8):860-865. PubMed ID: 30985507
[TBL] [Abstract][Full Text] [Related]
20. Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: The HERACLES clinical surveillance study.
Picazo JJ; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero-Artigao F; Hernández-Sampelayo T; Otheo E; Amo MD; Méndez C;
Vaccine; 2019 Apr; 37(16):2200-2207. PubMed ID: 30902478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
